AbbVie (ABBV)'s Battle For Shire: Why This Time It's Different
7/7/2014 6:43:49 AM
Just five weeks after Pfizer walked away from its £70bn attempt to buy AstraZeneca, another American suitor has come knocking on the door of a London-listed pharmaceutical company, lured by the tantalising prospect of the much lower tax rate that comes with a European domicile.
On the face of it, AbbVie’s $46bn (£27bn) pursuit of Shire looks to have more than just the brushstrokes of Pfizer and AstraZeneca – a US drugmaker, eyeing a UK target, with tax advantages at the forefront of rationale.
But the latest deal has failed to provoke the political furore that Pfizer’s bid for AstraZeneca ignited.
Help employers find you! Check out all the jobs and post your resume.
comments powered by